ReviewEJNMMI radiopharmacy and chemistry2023
State of the art procedures towards reactive [
Review in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Expanding the Medicinal Chemistry Toolbox for PET Imaging: AliphaticChemical & biomedical imaging · 2026Article
- Recent advances in [Nuclear medicine and biology · 2026Review
- Deoxyradiofluorination of Phenols via a Difluoromethoxy Nucleofuge Enabled by Organic Photoredox Catalysis.ACS central science · 2026Article
- Next-GenInternational journal of molecular sciences · 2026Article
- Synthesis of [RSC advances · 2026Article
- A simplified, robust protocol for [Scientific reports · 2025Article
- A Full-Spectrum Evaluation of Sigma-1 Receptor (S1R) Positron Emission Tomography (PET) Radioligands from Binding Affinity to Clinical Imaging.Molecules (Basel, Switzerland) · 2025Review
- High-efficiency [EJNMMI radiopharmacy and chemistry · 2025Article
- Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes.Current cardiology reports · 2025Review
- Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with AlBioconjugate chemistry · 2024Article
- Automation of Copper-MediatedMolecules (Basel, Switzerland) · 2024Article
- Improved automated one-pot two-step radiosynthesis of (S)-[EJNMMI radiopharmacy and chemistry · 2024Article
- A Fully Automated Synthesis of 14-(Pharmaceuticals (Basel, Switzerland) · 2024Article
- [Molecules (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPositron emission tomography (PET) is a powerful, non-invasive preclinical and clinical nuclear imaging technique used in disease diagnosis and therapy assessment. Fluorine-18 is the predominant radionuclide used for PET tracer synthesis. An impressive variety of new 'late-stage' radiolabeling methodologies for the preparation of MAIN BODY: Despite these developments, one outstanding challenge into the early key steps of the process remains: the preparation of reactive [
conclusionImproved, modified or even completely new fluorine-18 work-up procedures have been developed in the last decade with widespread use in base-sensitive nucleophilic
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.